---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088346"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:17:59.423832+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q2 2023: YUPELRI sales up 12% YoY; $80.5M in share buybacks

## Summary
- YUPELRI net sales recognized by Viatris: $55.0M, up 12% YoY; Theravance's 35% share implies $19.3M.
- YUPELRI retail TRx and new-to-product TRx hit all-time highs, up 26% and 53% YoY (Symphony Health).
- PIFR-2 enrollment nearing completion; top-line data late Q4 2023, disclosure expected Jan 2024.
- $80.5M share repurchases in Q2 2023 ($263.8M cumulative); $61.2M remaining in $325M program to complete by year-end.
- TRELEGY ELLIPTA Q2 global net sales $760M (+29% YoY); $50M milestone from Royalty Pharma if 2023 sales ≥ $2.9B.

## SEC filing metadata
- accession: 0001104659-23-088346
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/0001104659-23-088346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923088346/tm2322953d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088346
- JSON: https://secwatch.observer/filing/0001104659-23-088346.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.